(Q37123773)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18377805%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

review article

1 reference

title

Optimizing drug therapy in inflammatory bowel disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18377805%20AND%20SRC:MED&resulttype=core&format=json

inflammatory bowel diseases

5 January 2020

main subject

0 references

author

Arun Swaminath

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18377805%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Asher Kornbluth

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18377805%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

1 December 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18377805%20AND%20SRC:MED&resulttype=core&format=json

Current gastroenterology reports

5 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18377805%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18377805%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18377805%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

513-520

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18377805%20AND%20SRC:MED&resulttype=core&format=json

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

5 January 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11894-007-0068-2

6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial

21 January 2018

1 reference

12 December 2020

Infliximab in the treatment of Crohn's disease: a user's guide for clinicians

1 reference

12 December 2020

Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

1 reference

12 December 2020

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

12 December 2020

The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine

1 reference

12 December 2020

Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease

1 reference

12 December 2020

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

12 December 2020

Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype

1 reference

12 December 2020

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

1 reference

12 December 2020

Side effects of corticosteroid therapy

1 reference

12 December 2020

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.

1 reference

12 December 2020

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

12 December 2020

Once-daily, high-concentration MMX mesalamine in active ulcerative colitis

1 reference

12 December 2020

Bone density in young males with recently diagnosed inflammatory bowel disease

1 reference

12 December 2020

Continuous Infusion Versus Bolus Administration of Steroids in Severe Attacks of Ulcerative Colitis: A Randomized, Double-Blind Trial

1 reference

12 December 2020

Prevention and treatment of osteoporosis in inflammatory bowel disease

1 reference

12 December 2020

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

12 December 2020

Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis

1 reference

12 December 2020

Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression

1 reference

12 December 2020

Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis

1 reference

12 December 2020

Risk-Benefit Assessment of Drugs Used in the Treatment of Inflammatory Bowel Disease

1 reference

12 December 2020

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

1 reference

12 December 2020

Cortisone in ulcerative colitis; final report on a therapeutic trial.

1 reference

12 December 2020

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients

1 reference

12 December 2020

6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.

1 reference

12 December 2020

Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease

1 reference

12 December 2020

Cyclosporine for induction of remission in Crohn's disease

1 reference

12 December 2020

Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis

1 reference

12 December 2020

Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis

1 reference

12 December 2020

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

1 reference

12 December 2020

Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial

1 reference

12 December 2020

Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine

1 reference

12 December 2020

Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines' criteria

1 reference

12 December 2020

Review article: systemic and topical steroids in inflammatory bowel disease

1 reference

12 December 2020

A Comparison of Oral Prednisolone Given as Single or Multiple Daily Doses for Active Proctocolitis

1 reference

12 December 2020

Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study

1 reference

12 December 2020

A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine

1 reference

12 December 2020

Predictors of medication adherence in inflammatory bowel disease.

1 reference

12 December 2020

Osteoporosis in patients with inflammatory bowel disease

1 reference

12 December 2020

American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease

1 reference

12 December 2020

A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis

1 reference

12 December 2020

Management of Crohn's disease in adults

1 reference

12 December 2020

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

12 December 2020

The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study

1 reference

12 December 2020

10.1007/S11894-007-0068-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18377805%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference